Incorporated in October 2000, Molbio Diagnostics Limited is an international POC (Point of Care) molecular diagnostics company providing the research, development, manufacture, and marketing of rapid diagnostic tools for various infectious and non-communicable diseases. The company owns proprietary 'Truenat' platform – it is a portable, battery-driven PCR-based molecular diagnostics system that produces reliable tests in an hour. Molbio provides molecular diagnostics solutions for more than 30 diseases through 43 diagnostic tests that include tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. Besides, the company also provides radiology, digital pathology, and breast health screening services through its subsidiaries and strategic partnerships while continuously broadening the diagnostics products range through advanced R&D operations. There are six manufacturing sites of Molbio located in India and the company provides its products to over 90 countries worldwide through government health programs, diagnostic laboratories, hospitals, and other international healthcare companies. Supported with its patent portfolio, international certification, and strategic acquisitions, Molbio is recognized as the leader in innovations in molecular diagnostics. As of March 31, 2026, Molbio had 1,225 employees on permanent positions in research and development, manufacturing, quality control, sales, financial, and corporate departments.